MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-28-2024
CymaBay Therapeutics Total Shareholders Equity 2011-2026 | CBAY
Annual Total Shareholders Equity CymaBay Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 292 M | 36.2 M | 133 M | 143 M | 186 M | 170 M | 84.9 M | 3.94 M | 28.1 M | 13.8 M | 18.6 M | -329 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 292 M | -329 M | 65.1 M |
Quarterly Total Shareholders Equity CymaBay Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 326 M | 108 M | 104 M | 36.2 M | 60.2 M | 82.5 M | 107 M | 133 M | 87.1 M | 107 M | 128 M | 143 M | 143 M | 143 M | 143 M | 186 M | 186 M | 186 M | 186 M | 170 M | 170 M | 170 M | 170 M | 84.9 M | 84.9 M | 84.9 M | 84.9 M | 3.94 M | 3.94 M | 3.94 M | 3.94 M | 28.1 M | 28.1 M | 28.1 M | 28.1 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 18.6 M | 20.1 M | 18.6 M | 18.6 M | -329 M | -329 M | - | - | -305 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 326 M | -329 M | 63.4 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Cerus Corporation
CERS
|
64.2 M | $ 2.61 | 28.62 % | $ 497 M |  USA |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
1.37 B | $ 97.03 | -6.21 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 5.17 | 5.08 % | $ 820 M |  Britain |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
733 M | $ 21.91 | -2.41 % | $ 3.63 B | USA |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
15.6 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
Cardiff Oncology
CRDF
|
45.4 M | $ 1.72 | -0.87 % | $ 115 M | USA |
 |
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
8.38 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | USA |
 |
Caladrius Biosciences
CLBS
|
29.6 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
351 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Editas Medicine
EDIT
|
27.3 M | $ 2.91 | -3.0 % | $ 258 M | USA |
 |
Edesa Biotech
EDSA
|
1.98 M | $ 17.35 | -5.06 % | $ 55.5 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
597 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 3.03 | -5.02 % | $ 4.99 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
-14.5 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-10.7 M | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Evogene Ltd.
EVGN
|
56.9 M | $ 0.79 | 1.66 % | $ 27.9 M | Israel |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
15.8 M | $ 0.57 | 0.07 % | $ 2.46 M | Israel |